Insider Buy: Iveric Bio
5:05PM ET 6/14/2022 MT NewswiresCalvin W. Roberts, Director, on June 13, 2022, executed a purchase for 25,000 shares in Iveric Bio (ISEE) for $240,500. Following the Form 4 filing with...
Quotes Snapshot > ISEE
IVERIC bio Inc ISEE:NASDAQ
Last Price$10.26Cboe Real-Time Last Sale as of 10:09AM ET 6/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.18(1.72%)
Bid (Size)$10.26 (206)
Ask (Size)$10.27 (33)
Day Low / High$10.17 - 10.54
Volume100.5 K
Read more news Recent News
IVERIC Bio Shares Rise After BofA Securities, Guggenheim Start Coverage at Buy
1:02PM ET 6/08/2022 MT NewswiresIVERIC Bio (ISEE) shares were up 2.6% in Wednesday midday trading after BofA Securities started coverage of the company with a buy rating and $18 price...
--Guggenheim Starts IVERIC bio at Buy With $30 Price Target
8:09AM ET 6/08/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
BofA Securities Starts IVERIC bio at Buy With $18 Price Target
6:31AM ET 6/08/2022 MT NewswiresIVERIC bio (ISEE) has an average rating of outperform and price targets ranging from $12 to $28, according to analysts polled by Capital IQ. (MT Newswires...
View all Commentary and Analysis
IVERIC bio: A First Take
2:16PM ET 6/23/2022 Seeking AlphaBiopharmaceutical Stocks: The Bottoming Process Is Playing Out
2:30PM ET 6/08/2022 Seeking AlphaIVERIC (ISEE) Investor presentation - Slideshow
10:10AM ET 5/07/2022 Seeking AlphaIVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2022 Results - Earnings Call Transcript
2:04PM ET 5/04/2022 Seeking AlphaCompany Profile
Business DescriptionIVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. View company web site for more details
| Address | 8 Sylvan Way Parsippany, New Jersey 07054 |
| Phone | +1.609.474.6755 |
| Number of Employees | 35 |
| Recent SEC Filing | 06/14/2022 4 |
| Chief Executive Officer & Director | Glenn P. Sblendorio |
| President | Pravin U. Dugel |
| Chief Operating Officer & Senior Vice President | Keith Westby |
| Chief Financial Officer, Treasurer & Senior VP | David F. Carroll |
Company Highlights
| Price Open | $10.44 |
| Previous Close | $10.44 |
| 52 Week Range | $5.96 - 19.35 |
| Market Capitalization | $1.2 B |
| Shares Outstanding | 116.4 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/03/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.13 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -46.15% |
Analyst Ratings as of 06/08/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |